AR and metastatic prostate carcinoma: Despite initial treatment responses from treating aggressive primary and metastatic prostate cancer through castration to suppress AR signaling4, resistance ensues as 80% of mCRPC tumors harbor either AR gene amplification, amplification of a CRE upstream of AR, or activating AR coding mutations11,55,62.